Physician profile
Monica Schepp
NPI 1134672967
$1,658.49
in general payments reported to CMS, 2019-2025
19 companies · $738 in 2025
The $738 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $177 · 2023: $219 · 2024: $409 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.32 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $398.30 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $229.69 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $220.41 | 2021-2025 | |
| Amgen INC. | $126.62 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $78.07 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $75.84 | 2024-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $70.51 | 2021-2025 | |
| Lilly USA, LLC | $68.32 | 2021-2022 | |
| Genzyme Corporation | $64.56 | 2022-2025 | |
| Incyte Corporation | $62.70 | 2023-2024 | Opzelura |
| Mayne Pharma Commercial LLC | $55.39 | 2025 | |
| Kerecis Limited | $37.00 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Epi Health, LLC | $32.38 | 2022 | |
| Arcutis Biotherapeutics, INC. | $31.26 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $22.71 | 2023 | Vtama |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $22.28 | 2025 | Spinosad, Natroba |
| Organon LLC | $22.03 | 2025 | Hadlima |
| Sun Pharmaceutical Industries INC. | $20.77 | 2024 | |
| Galderma Laboratories, L.P. | $19.65 | 2024 | Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Schepp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.